MEVION S250i Proton Therapy System with Hyperscan pencil beam scanning. Credit: Mevion Medical Systems.

Mevion Medical Systems has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for its MEVION S250i Proton Therapy System to deliver conformal radiation therapy treatment.

The compact system features Hyperscan pencil beam scanning (PBS) technology that provides energy layer switching and automated collimation systems for enabling rapid and sharp proton treatments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hyperscan PBS’ compact beam delivery path is said to minimise delivery times to lower than five seconds for certain fields, leading to decreased treatment errors, compared to other PBS technologies.

The PBS also uses the Adaptive Aperture proton multi-leaf collimator (pMLC), which is a robotically controlled collimation system with the ability to trim beam edges at every delivery layer.

“This is a very important milestone in our efforts to make precision proton therapy available to more patients in the fight against cancer.”

This capability of the collimator is claimed to result in three times sharper radiation drop off at the delivery field edge, improving sparing of healthy tissue and limiting unnecessary radiation to sensitive locations.

Mevion Medical Systems CEO Joseph Jachinowski said: “The S250i system represents the next generation of intensity modulated proton therapy (IMPT) delivered in the most compact proton therapy platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This is a very important milestone in our efforts to make precision proton therapy available to more patients in the fight against cancer.”

The firm has installed the first MEVION S250i Proton Therapy System at MedStar Georgetown University Hospital in Washington DC, US, to be offered as part of the hospital’s suite of cancer care offerings.